BioMarin price target raised to $60 by HC Wainwright
HC Wainwright & Co. raised its BioMarin Pharmaceutical price target to $60.00/share from $59.00.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.